Vesalius Cardiovascular Inc.
We are a preclinical medical device company in the structural heart space. We are developing a Transfemoral Mitral Valve Repair (TMVr) solution for a very common heart valve disease called Degenerative Mitral Regurgitation.
Our TMVr solution uses pre-established techniques (transfemoral-transseptal delivery, annuloplasty, and chordal replacement) and is based on current surgical principles; we are reproducing proven surgical results without the need for surgery.
Our solution eliminates the burden associated with surgery and allow the treatment of almost all patients suffering from the underlying disease.
We are based in Vancouver, Canada.
on the treatment of degenerative mitral valve disease causing mitral regurgitation.
is the percutaneous treatment of degenerative mitral regurgitation with a novel medical device that respect the proven principles of mitral valve surgery.
Who We are
The Management Team
Dr. Peter Skarsgard, MD
Chief Scientific Officer
Dr. Skarsgard is a Cardiovascular Surgeon and Clinical Associate Professor of Surgery at the University of British Columbia, and Head of the Division of Cardiovascular Surgery at Vancouver General Hospital. His area of expertise is mitral valve repair and complex valvular surgery. Based upon a simple clinical observation, Dr. Skarsgard developed and patented concepts for devices aimed toward percutaneous treatment of mitral regurgitation, utilizing proven surgical principles. These ideas form the basis for Calla and Orion.
Vincent Ledoux, MSc
Chief Operating Officer
Mr. Ledoux is a Business Specialist with over 23 years experience in Investment Banking, Corporate Management and Startups. During his tenure at BNP Paribas, the largest bank in Europe, he successfully held several roles internationally and completed the prestigious General Inspection program within the group. Since 2009, he has been deeply involved in Canadian engineering and medical device startups. Vincent holds an MSc in Business Management from EMLyon Business School. Vincent manages the day-to-day activities and coordinates the R&D.
Ryan Harrington, MEng
Head of Engineering
Mr. Harrington is a Mechanical Engineer with over 8 years experience in engineering design and development, with a primary focus on cardiovascular implants. He was one of the first engineers to join Vesalius and grew with the company to lead the current team of 8 handpicked biomedical engineers. Ryan holds a Master of Engineering degree from University College Dublin in Ireland. He is responsible for all engineering aspects of the device development and regulatory affairs.
The Clinical Advisory
Dr. Jacqueline Saw, MD
Interventional Cardiology Advisor
Dr. Saw is a Clinical Professor of Medicine at the University of British Columbia, and a Structural Interventional Cardiologist at the Vancouver General Hospital. She is a recognized expert and key opinion leader in percutaneous device delivery, left atrial appendage occlusion, and spontaneous coronary artery dissection. Her contributions in CT imaging, pre-procedural planning, device selection, and device delivery have enabled acceleration of evolving structural interventions. She has considerable clinical trial experience, and has been a driving force for understanding women’s health in cardiovascular disease. Dr. Saw will lead the pre-procedure planning and device delivery effort, and bring important clinical trial design input to Vesalius Cardiovascular.
Dr. Christopher Durkin, MD
Dr. Durkin is a Clinical Assistant Professor of Anaesthesiology at the University of British Columbia, and a member of the Section of Cardiovascular Anaesthesiology at Vancouver General Hospital. In addition to expertise in cardiovascular physiology and pharmacology, he holds National Board of Echocardiography Certification in Advanced Perioperative Transesophageal Echocardiography, and is an expert in 3D echo for intracardiac structural disease and procedures. Dr. Durkin brings critical inputs in 3D echo imaging, both procedurally and in planning, to Vesalius Cardiovascular.